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Abstract: 
Background: This thesis describes the effects of smokeless tobacco (ST) and its derivatives on the oral 
mucosa; the development of, and results of applying a cessation program for snuff users with long and 
extensive exposure; and the persistent clinical and histomorphological changes after cessation. 
Methods: Three of the studies were open prospective non-randomized clinical intervention trials using 
nicotine replacement therapy (NRT) of either 4 mg nicotine chewing gum or 2 mg nicotine lozenges. 
Clinical examinations, biopsies, and histomorphological analyses were performed. In the fourth study in 
vitro assays were performed to investigate the effect of snuff extract, alkaloids, and selected tobacco-
specific nitrosamines (TSNA) on the accessory function of rat oral epithelium cells and T cells. 
Results: Of 280 participants motivated to discontinue snuff use, 50 were selected to treatment. After 3, 6, 
and 12 months, 58%, 46%, and 30% respectively were tobacco abstinent. Compliance was confirmed by 
measuring cotinine and carbon monoxide (CO) levels. Four subjects were still on NRT after 12 months, 
but tobacco-free since baseline. Twenty subjects abstinent after 6 months had a second biopsy from the 
site of snuff application. Of these, 40% showed remaining clinical lesions, the most significant of which 
were seen in the 75% of subjects still using NRT. The histomorphological picture was dominated by 
reductions in epithelial thickness, keratinization, and inflammatory response after tobacco cessation, 
although 30% of subjects showed increased epithelial thickness and 35% had increased or constant 
inflammatory reaction. A shift from ortho- to parakeratinization was noted in 80% of lesions. Of 30 
individuals who used lozenges for 6 months, 8 presenting lesions had a significantly higher nicotine 
exposure (p<0.05) than those without lesions. All lesions appeared between 1 and 6 weeks after treatment 
began. After 3 months of NRT, all lesions had resolved but one, which was healed at the 6-month control. 
In the mitogen (concanavallin A) driven in vitro model using rat oral epithelium cells with accessory 
Langerhans cells (LC), T cells incubated with various concentrations of extract of Swedish moist snuff 
(SS) showed a significant inhibition of cell proliferation at 12.5% (p<0.05), and a concentration of 4% 
reduced T cell proliferation by 50%. Alkaloids and TSNAs in concentrations similar to those in SS had no 
significant effect on cell proliferation. No mitogenic capacity was detected in the SS extract, alkaloids, or 
TSNA, although N′-nitrosonornicotine (NNN) showed a tendency to be stimulatory in an in vitro assay 
with T-cells and rat oral epithelial cells. 
Conclusion: Snuff cessation with NRT is a promising way to achieve a tobacco-free state. Compliance to 
treatment was high regardless of outcome, although almost all subjects gained weight, which correlated 
with a significant increase both in diastolic blood pressure in the success group and in total cholesterol 
values. Tissue samples from those with extensive exposure to snuff who were still using NRT on a daily 
basis 6 months after cessation were neither clinically nor histomorphologically completely normal. SS 
extract can evoke an immunosuppressive effect on T-cell proliferation using cells from oral epithelium as 
accessory cells. This effect was more pronounced when the complete SS extract was employed compared 
to when single components were used. These findings may indicate a local immunosuppressive effect of 
ST on the oral mucosa. Daily repeated sublingual exposure to nicotine for 3 months appears to be a safe 
form of administration with mild and transient effects in individuals devoid of clinical lesions. 
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